The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
 
Rosalind Margaret Glasspool
Consulting or Advisory Role - Clovis Oncology
Research Funding - Boehringer Ingelheim (Inst); Ignyta (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Sarah Patricia Blagden
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Nucana
 
Michelle Lockley
No Relationships to Disclose
 
James Paul
No Relationships to Disclose
 
Carol Hopkins
No Relationships to Disclose
 
Fiona Thomson
Stock and Other Ownership Interests - AstraZeneca; Merck
Consulting or Advisory Role - Bionomics; Merck
 
Jennifer Brown
Travel, Accommodations, Expenses - Amgen
 
Ricardo Fernandes
No Relationships to Disclose
 
Nivea Douglas
Travel, Accommodations, Expenses - Novartis
 
Chantevy Pou
No Relationships to Disclose
 
Aishah Hanif
Consulting or Advisory Role - Decision Resources
 
Craig Campbell
No Relationships to Disclose
 
Pratik S. Multani
Employment - Ignyta
Leadership - Ignyta
Stock and Other Ownership Interests - Ignyta
 
Trevor Tucker
Employment - Ignyta; Lilly
 
Iain A. McNeish
Consulting or Advisory Role - Clovis Oncology
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); ImmunoGen (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb